Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications. by Cohen, Philip R & Kurzrock, Razelle
UC San Diego
UC San Diego Previously Published Works
Title
Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and 
Potential Therapeutic Implications.
Permalink
https://escholarship.org/uc/item/74v540g2
Journal
Dermatology and therapy, 5(2)
ISSN
2193-8210
Authors
Cohen, Philip R
Kurzrock, Razelle
Publication Date
2015-06-01
DOI
10.1007/s13555-015-0074-5
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CASE REPORT
Merkel Cell Carcinoma with a Suppressor of Fused
(SUFU) Mutation: Case Report and Potential
Therapeutic Implications
Philip R. Cohen . Razelle Kurzrock
To view enhanced content go to www.dermtherapy-open.com
Received: February 27, 2015 / Published online: April 15, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Merkel cell carcinoma is a
neuroendocrine malignancy. Suppressor of
fused (SUFU) is a tumor suppressor oncogene
that participates in the Hedgehog (Hh)
signaling pathway. The aim of the study was
to describe a patient whose Merkel cell
carcinoma demonstrated a SUFU genomic
alteration.
Case Study: The Hh signaling pathway is
involved in the pathogenesis of several
tumors, including nevoid basal cell carcinoma
syndrome that is associated with an alteration
of the patched-1 (PTCH1) gene. Targeted
molecular therapy against smoothened (SMO)
with vismodegib has been shown to be an
effective therapeutic intervention for patients
with PTCH-1 mutation. The reported patient
was presented with metastatic Merkel cell
carcinoma. Analysis of his tumor, using a
next-generation sequencing-based assay,
demonstrated a genomic aberration of SUFU
protein, a component of the Hh signaling
pathway that acts downstream to SMO and,
therefore, is unlikely to be responsive to
vismodegib. Of interest, arsenic trioxide or
bromo and extra C-terminal inhibitors impact
signals downstream to SUFU, making this
aberration conceivably druggable. His tumor
has initially been managed with chemotherapy
(carboplatin and etoposide) and subsequent
radiation therapy is planned.
Conclusion: The pathogenesis of Merkel cell
carcinoma is multifactorial, and related to
ultraviolet radiation exposure,
immunosuppression, and Merkel cell
polyomavirus. We report a patient with a
mutation in SUFU, a potentially actionable
component of the Hh signaling pathway.
Electronic supplementary material The online
version of this article (doi:10.1007/s13555-015-0074-5)
contains supplementary material, which is available to
authorized users.
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INTRODUCTION
Merkel cell carcinoma is an aggressive
neuroendocrine cancer of the skin [1].
Suppressor of fused (SUFU), an integral
component of the Hedgehog (Hh) signaling
pathway, functions as a tumor suppressor gene
[2]. A man with metastatic Merkel cell
carcinoma is described whose tumor was
associated with a SUFU genomic aberration.
Potential therapeutic interventions based upon
this unique abnormality of his tumor are
postulated.
CASE REPORT
A 66-year-old Caucasian man was referred for an
evaluation of an asymptomatic left buttock
mass that he had noticed 6 months earlier. His
past medical history was significant for prostate
cancer at age 64 years (stage T1c Gleason grade
3 ? 3) that was successfully treated with
intensity-modulated radiation therapy. His
pretreatment and posttreatment nadir
prostate-specific antigen were 4.5 and 0.88
nanograms per milliliter, respectively.
A month prior to his skin evaluation, he was
being worked up for a possible left inguinal
hernia repair. His computerized axial
tomographic scan showed enlargement of the
left inguinal, left pelvic sidewall and
retroperitoneal lymph nodes and a soft tissue
nodule in his left buttock. His surgeon
performed a superficial inguinal lymph node
biopsy that showed a high-grade
neuroendocrine carcinoma; the tumor cells
stained positive for CD56 (neural cell adhesion
molecule), chromogranin, cytokeratin 20,
cytokeratin AE1/AE3, and synaptophysin. The
tumor cells were negative for CD45 (leukocyte
common antigen), GATA3 (trans-acting T cell-
specific transcription factor) and prostate-
specific antigen. The morphologic and
immunohistochemical features indicated a
metastatic Merkel cell carcinoma.
He also had a history of multiple lipomas. He
had considered the left buttock nodule, which
he initially noticed 6 months earlier, to be
another lipoma; however, it continued to
increase in size. A positron emission
tomography (PET)/computed tomography (CT)
scan, which was performed after receiving the
lymph node biopsy pathology report of
metastatic Merkel cell carcinoma,
demonstrated intense fluorodeoxyglucose
uptake from the soft tissue density in the
subcutaneous tissue of the left buttock. This
was suspicious for a primary tumor.
Fig. 1 Distant (a) and closer (b) views with ink
demarcating the borders of the primary Merkel cell
carcinoma on the left buttock nodule of a 66-year-old
man
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Cutaneous examination (1 month after the
lymph node biopsy and 6 months after the
patient’s discovery of a left buttock mass)
showed a painless flesh-colored 3 9 3 cm
subcutaneous nodule with central erythema
on his left buttock (Fig. 1). The nodule was
firmly grasped and pushed toward the skin
surface as a punch biopsy using a 4-mm
circular blade was performed into its center. A
cylindrical core specimen of tissue, extending
from the epidermis to beyond the deep dermis,
was obtained. The nodule was then firmly
squeezed and additional aggregates of tumor
(appearing yellowish-white and blood tinged)
that extruded through the biopsy wound were
collected (Fig. 2).
Microscopic examination of the skin biopsy
specimen showed an infiltrate of small blue cells
with minimal cytoplasm in the deep portion of
the punch biopsy and all the pieces of
subcutaneous tissue (Fig. 3). The basophilic
cells were uniform in size with a vesicular
nucleus and small nucleoli. Numerous mitoses
were appreciated and there were large areas of
Fig. 2 Gross examination of the punch biopsy specimen
shows a cylindrical piece of tissue secured using the 4-mm
circular blade and several blood-tinged yellowish-white
lobules of tumor (morphologically mimicking adipose
tissue). These were expressed through the hole created
during the biopsy after applying firm pressure to the tumor
Fig. 3 Tumor is present at the base of the punch biopsy
specimen. It is in the deep dermis and extends into the
subcutaneous tissue [hematoxylin and eosin, 92]
Fig. 4 Distant (a) and closer (b) views of hematoxylin and
eosin stained sections show the blue small cell tumor that
extends from the deep dermis into the subcutaneous tissue
[hematoxylin and eosin; a = 94, b = 920]
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necrosis. The tumor invaded fascia in the deeper
specimens and focally grew in close
approximation to multiple blood vessels;
however, no intravascular or perineural
invasion was identified (Fig. 4).
Immunohistochemical studies showed that
the tumor cells stained positive for cytokeratin
20 (in a cytoplasmic and paranuclear dot-like
pattern), CD56 (neural cell adhesion molecule),
and synaptophysin (Fig. 5). The tumor cells
were negative for prostate-specific antigen and
thyroid transcription factor 1.
Correlation of the history, clinical
morphology, imaging studies, and pathology
was diagnostic for metastatic Merkel cell
carcinoma. The left buttock was the site of the
primary tumor. Metastases had spread to the
regional lymph nodes.
The biopsy tissue from the left buttock
tumor was also sent for genomic evaluation. A
next-generation sequencing-based assay was
performed. Genomic alterations of our
patient’s tumor, evaluated by next-generation
sequencing included base substitutions,
insertions, deletions, and copy number
alterations [3].
DNA was extracted from 40 micrometer of
formalin-fixed tissue (minimum 20% tumor
cells) using the Maxwell 16 FFPE Plus LEV
DNA Purification kit (Promega, Wisconsin,
USA) and quantified using a standardized
PicoGreen fluorescence assay (Invitrogen).
Library construction was performed using
50-200 nanogram of DNA sheared by
sonication to approximately 100–400 base
pairs before end-repair, dA addition and
ligation of indexed Illumina sequencing
adaptors (Illumina, Inc., San Diego, CA, USA).
Enrichment of targeted sequences (including all
coding exons of 315 cancer related genes) plus
introns from 28 genes often rearranged or
altered in cancer (Table 1) [4] was achieved by
solution-based hybrid capture with custom
biotinylated oligonucleotide bases. Enriched
libraries were sequenced to an average median
depth of[5009 with 99% of bases
covering[1009 [Illumina HiSwq 2000
(Illumina, Inc.) platform using 49 9 49 paired-
end reads] and mapped to the reference human
genome (hg19) using the Burrows–Wheeler
Aligner and the publicly available SAMtools,
Picard, and Genome Analysis Toolkit. Point
mutations were identified by a Bayesian
algorithm; short insertions and deletions,
Fig. 5 The tumor shows positive staining for cytokeratin
20 (a), CD56 (b) and synaptophysin
(c) [immunoperoxidase: cytokeratin 20, a = 940; CD56,
b = 940; synaptophysin, c = 940]
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determined by focal assembly; gene copy
number alterations (amplification), by
comparison to process matched normal
controls; and gene fusions/rearrangements, by
clustering chimeric reads mapped to targeted
introns. Amplifications were called for C6
copies except for ErbB2 (C5 copies). Six to
seven copy numbers are called as equivocal
and C8 are definitive; for ErbB2, equivocal
amplification was 5–7 copies; all (equivocal or
definitively amplified) were designated as
positive for amplification in our patient.
Aberrations, mutations or other alterations in
kinases that were presumed to be inactivating
based on wet lab experiments or structural
modeling were not included [5].
Alterationof the SUFUgene [SUFUR299Q(due
to nucleotide mutation at position 299, arginine
becomes glutamine in the SUFOprotein)] was the
only abnormality identified by the next-
generation sequencing-based assay (315 gene
panel; Foundation Medicine, Inc., Cambridge,
MA, USA) [4]. Treatment with systemic
chemotherapy was initiated with carboplatin
and etoposide. He is receiving treatment every
3 weeks and adjuvant radiotherapy is planned.
Follow-up evaluation shows decrease in the size
of the left buttock tumor and the previously
enlarged lymph nodes. Consideration to use
experimental agents that target the distal Hh
pathwaymaybeconsidered ifhis tumorprogresses.
Informed consent was obtained from the
patient for being included in the study and for
publication of the images.
DISCUSSION
Merkel Cell Carcinoma
Merkel cell carcinoma was initially described by
Toker in 1972 as trabecular carcinoma of the
skin [1]. It is a biologically aggressive tumor
with a poor prognostic outcome resulting from
local, regional and distant recurrences. Older
men are more commonly affected and the
primary tumor is usually located on sun-
exposed skin [1, 6, 7].
Merkel cell carcinoma usually presents as an
asymptomatic rapidly enlarging flesh-colored or
blue-red nodule [6, 8]. In our patient, the tumor
clinically appeared as a firm red nodule below
the skin surface. Its gross appearance, yellow-
white lobules, was similar in morphology to
adipose tissue.
Histologically, Merkel cell carcinoma is a
tumor composed of small monomorphous blue
cells, often arranged in strands (trabeculae),
which demonstrate numerous mitoses,
apoptotic cells and occasional necrosis. The
tumor shows a positive paranuclear dot-like
pattern of staining for cytokeratin 20. In
addition, the immunoperoxidase profile of the
tumor often includes positive staining for CD56
(neural cell adhesion molecule), chromogranin
A, gastrin, and somatostatin [6, 8, 9].
Non-invasive imaging methods (fluorine-18-
fluorodeoxyglucose PET and CT) are typically
used to assess the extent of disease in patients
with Merkel cell carcinoma. They may be
performed during the initial staging of the
patient when distant metastases are suspected
or when a cutaneous metastasis from a
noncutaneous primary neuroendocrine
carcinoma is considered [7, 10, 11]. Our
patient had a history of multiple lipomas and
presented with metastatic Merkel cell
carcinoma to his left inguinal lymph node. His
PET scan identified the primary tumor: a large
and rapidly growing deep dermal nodule of his
left buttock that had clinically been considered
to be a lipoma.
The treatment of primary cutaneous Merkel
cell carcinoma is a wide local surgical excision
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and sentinel lymph node biopsy. A positive
sentinel lymph node may be followed by a
complete lymph node dissection. Adjuvant
radiotherapy is often included for patients
with positive sentinel lymph nodes and
considered in patients with tumors of the head
and neck region that have a negative sentinel
lymph node because of the higher risk of a false-
negative result [1, 6–8].
The management of metastatic Merkel cell
carcinoma includes a variety of treatments.
Chemotherapy most often utilized platinum
with or without etoposide. Although the tumor
often initially responds to therapy, resistance
frequently develops after two or three cycles of
chemotherapy. Other treatments included
radiation therapy and experimental novel
approaches such as immunotherapy and
targeted molecular therapy [1, 7, 12].
Exposure to ultraviolet radiation (such as
psoriasis patients receiving psoralen and
ultraviolet A therapy), immunosuppression
(such as in AIDS patients, individuals with
chronic lymphocytic leukemia, and organ
transplant recipients) and Merkel cell
polyomavirus infection are risk factors for the
development of Merkel cell carcinoma [6, 12–
15]. Merkel cell polyomavirus was discovered in
2008 [9, 16]. The virus is present in
approximately 80 percent of Merkel cell
carcinomas [17]. Indeed, there is improved
survival for patients whose Merkel cell
carcinoma is virus-positive as compared
individuals with virus-negative tumors [14,
18]. However, the presence of Merkel cell
polyomavirus is not specific for Merkel cell
carcinoma. The virus has also been
demonstrated in other malignancies, including
cervical carcinoma [19], chronic lymphocytic
leukemia [20], cutaneous squamous cell
carcinoma [21], folliculotropic mycosis
fungoides [22, 23], Langerhans cell sarcoma
[24], and small cell carcinoma (extrapulmonary
[25] and parotid [26]). In addition, although
one group of researchers have found an
association between Merkel cell polyomavirus
infection and epidermal growth factor hotspot
mutations in non-small-cell lung cancer [27],
there is currently no evidence of an association
between the virus and any specific genomic
aberration—including a mutation in SUFU
protein—in Merkel cell carcinoma [28].
Mutational analysis of Merkel cell carcinoma
has revealed numerous abnormalities including
mutations in telomerase activation, tumor
suppressors, and tyrosine kinase signaling
(Table 2) [9, 29]. Chromosomal analysis,
utilizing comparative genomic hybridization
to define copy number abnormalities (such as
amplified or deleted regions) on chromosomes
but not specific genes, has also found several
chromosomal aberrations [9, 30]. A genomic
alteration in SUFU protein—an integral
Table 2 Mutations in telomerase activation, tumor
suppressors and tyrosine kinase signaling in Merkel cell
carcinoma
Telomerase activation mutations and amplifications
TERT (telomerase reverse transcriptase) promoter
Tumor suppressor mutations
RB1 (human retinoblastoma gene)
SUFU (suppressor of fused)
TP53 (tumor protein p53)
Tyrosine kinase signaling mutations
AKT (protein kinase B)
KIT (also known as CD117 or mast/stem cell growth
factor receptor)
PDGFRA (platelet-derived growth factor receptor,
alpha)
PIK3CA (phosphatidylinositol-4,5-bisphosphate
3-kinase, catalytic subunit alpha)
PTEN (phosphatase and tensin homolog)
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component of the Hh signaling pathway—was
identified in our patient’s Merkel cell carcinoma
using a next-generation sequencing-based
assay. Although one group of investigators
detected over expression of Hh signaling
pathway proteins in the Merkel cell
carcinomas they studied [31], to the best of
our knowledge, neither Merkel cell carcinoma
associated with a SUFU protein mutation nor
Merkel cell carcinoma related to a genomic
aberration of the Hh signaling pathway has
previously been described.
Hedgehog Signaling Pathway
The Hh signaling pathway has an essential role
in not only embryonic development but also
cell differentiation and proliferation. The term
‘hedgehog’ was introduced to describe the
appearance (similar to that of the spiky
hedgehog) of the mutated gene in the larva of
the fruit fly Drosophila melanogaster. The Hh
signaling pathway is suppressed in the majority
of normal human cells [2, 32, 33].
In mammals, the primary cilium of the cell
membrane contains a receptor and a signal
transducer. The twelve-pass transmembrane
receptor patched-1 (PTCH1) inhibits the seven-
pass transmembrane G-coupled receptor-like
protein smoothened (SMO). This allows for
the intracellular inhibition of the associated
oncogene glioma-1/2 transcription factor
function by (SUFU) protein [2, 32, 34, 35].
The binding of the Hh ligand to the PTCH1
receptor activates the Hh signaling pathway. In
humans, there are three Hh ligands: (1) sonic
hedgehog (named after the Sega videogame and
implicated in establishing left–right symmetry
and development of the central nervous system,
eyes and muscles), (2) desert hedgehog (named
after a real hedgehog species and implicated in
the development of male germ cells), and (3)
Indian hedgehog (named after a real hedgehog
species and implicated in the development of
cartilage and regulation of bone growth).
Binding of the Hh ligand to PTCH1 receptor
(or the presence of a mutation in either the
PTCH1 or SMO signal transducer) removes the
suppression of SMO by PTCH1. This results in
the inhibition of the regulation by SUFU
protein and the subsequent release of glioma
transcription activity in the nucleus [2, 32, 33,
36, 37].
The Hh signaling pathway plays a role in the
development and persistence of human cancers.
Constitutive activation of the Hh signaling
pathway is involved in tumorigenesis of
nevoid basal cell carcinoma syndrome (which
is also known as Gorlin–Goltz syndrome or
Gorlin syndrome) and associated with cancers
that have a mutation in the PTCH1 gene: basal
cell carcinoma, medulloblastoma, meningioma,
and rhabdomyoblastoma. Hyperactivity of the
Hh signaling pathway has also been linked to
the development of other cancers including
breast, colon, gastric, leukemias, lung, multiple
myeloma, pancreas and prostate. In addition,
aberrant activation of the Hh signaling pathway
has been demonstrated to contribute not only
to the maintenance and expression of leukemic
stem cells, but also to chemotherapy resistance
(in ovarian cancer, cervical cancer, and myeloid
leukemia cells) and radiotherapy resistance (in
pancreatic cancer and head and neck cancer) [2,
32, 38, 39].
Targeted therapy that affects the Hh
signaling pathway—specifically with
vismodegib that is an inhibitor of SMO—has
shown efficacy in the treatment of locally
advanced and metastatic basal cell carcinoma
and other tumors with patched-1 mutations
[34, 36, 40–45]. However, some patients’ basal
cell carcinomas have acquired resistance to
vismodegib [33, 46, 47]. Therefore, therapeutic
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agents that target downstream molecules in the
Hh signaling pathway, distal to SMO, are being
developed [38].
Suppressor of Fused Protein
SUFU is an intracellular negative regulator of
the Hh signaling pathway. It is a tumor
suppressor protein. SUFU functions by
modulating the activity of glioma
transcription factors [48–51]. SUFU mutation
(R299Q), as seen in our patient, has previously
been described in other cancers [52].
Mutations of SUFU have also been discerned
in patients with either idiopathic or nevoid
basal cell carcinoma syndrome-associated
medulloblastomas [53–61]. Less than one
percent (3/351) of cutaneous melanomas in
The Cancer Genome Atlas (TCGA) dataset
have a SUFU mutation [62]. To our knowledge,
our patient represents the initial observation of
this unique Hh signaling pathway aberration in
Merkel cell carcinoma.
The SUFU protein acts downstream of SMO
in the Hh signaling pathway. Therefore, it is
expected that targeted therapeutic
intervention using an inhibitor to SMO, such
as vismodegib, would not be effective for
individuals whose tumors were associated
with a SUFU mutation. Indeed, SMO
inhibitors failed to stop the growth of tumors
in SUFU-mutant mouse cancer models and
tumor-derived xenografts from a
medulloblastoma patient that harbored a
SUFU suppressor alteration [2, 56, 63].
Therapies that target the Hh signaling
pathway downstream of SUFU—affecting glial
transcription factors—may be appropriate for
individuals whose cancer harbors a SUFU
mutation, such as our patient’s Merkel cell
carcinoma [2, 36, 64–66]. These may include
agents such as arsenic trioxide that inhibits glial
transcription factors [67–69] and bromo and
extra C-terminal (BET) inhibitors that result in
downregulation of glial transcriptional activity
by inhibiting the BET bromodomain-containing
protein 4 [70–72]. Treatment with BET
inhibitors—such as JQ1 and OTX015—have
not only resulted in the inhibition SUFU-
mutant medulloblastoma growth but also have
shown clinical activity in the treatment of
patients with hematologic malignancies (such
as acute myelogenous leukemia and
lymphoma), respectively [70–72].
CONCLUSION
Merkel cell carcinoma is an aggressive
neuroendocrine tumor typically presenting on
sun-exposed skin of older men. In addition to
ultraviolet radiation, immunosuppression and
Merkel cell polyomavirus have been associated
with the development of Merkel cell carcinoma.
Chromosomal and mutational analysis of
Merkel cell carcinoma has demonstrated
several aberrations; however, neither a
unifying abnormality nor an alteration in the
Hh signaling pathway has been discovered. Our
patient’s metastatic Merkel cell carcinoma has a
unique, previously undescribed, genomic
aberration: a SUFU abnormality was the sole
alteration detected using a next-generation
sequencing-based assay. We hypothesize that
his tumor will not respond to inhibitors of
SMO, such as vismodegib, since these agents act
on the Hh signaling pathway upstream of the
patient’s SUFU abnormality. However, we
speculate that his Merkel cell carcinoma may
be successfully treated with therapy that targets
the Hh signaling pathway downstream to SUFU
protein—such as arsenic trioxide or BET
inhibitors—that result in downregulation of
glial transcription activity.
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